ProRx Pharma, the leading health and wellness 503B outsourcing facility, announced today it has been awarded a DEA Controlled Substances Registration Certificate, authorizing the company to handle and distribute select controlled substances. This milestone enhances ProRx’s ability to support providers with a broader range of compliant, high-quality medications.
“Earning our DEA Controlled Substances Registration Certificate is a pivotal moment for ProRx,” said Kurt Lunkwitz, chief operating officer at ProRx. “It not only enables us to expand into compounding and distributing Schedule III substances like testosterone, but also demonstrates our commitment to regulatory excellence. This certification strengthens our ability to serve providers with trusted therapies, expand partnerships, and support long-term business growth.” Read More >
